Semnur Pharmaceuticals, Inc.
SMNR
$0.55
-$0.01-1.79%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6,222.36% | 5,470.26% | 5,194.10% | 5,328.21% | 21.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4,382.40% | 4,169.34% | 3,320.38% | 3,101.53% | -16.43% |
| Operating Income | -4,382.40% | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% |
| Income Before Tax | -4,385.69% | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4,385.69% | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4,385.69% | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% |
| EBIT | -4,382.40% | -4,169.34% | -3,320.38% | -3,101.53% | 16.43% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4,304.81% | -3,831.07% | -2,870.79% | -2,588.11% | 32.97% |
| Normalized Basic EPS | -4,300.00% | -3,823.26% | -2,868.86% | -2,584.36% | 32.76% |
| EPS Diluted | -4,304.81% | -3,831.07% | -2,870.79% | -2,588.11% | 32.97% |
| Normalized Diluted EPS | -4,300.00% | -3,823.26% | -2,868.86% | -2,584.36% | 32.76% |
| Average Basic Shares Outstanding | 9.94% | 11.75% | 13.77% | 17.90% | 25.00% |
| Average Diluted Shares Outstanding | 9.94% | 11.75% | 13.77% | 17.90% | 25.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |